Stockreport

Novo Nordisk's ocedurenone Phase III flop costs company $816m [Yahoo! Finance]

Novo Nordisk A/S  (NVO) 
Last novo nordisk a/s earnings: 2/5 01:31 am Check Earnings Report
US:NYSE Investor Relations: novonordisk.com/investors.html
PDF The Phase III CLARION-CKD trial (NCT04968184) failed to meet its primary endpoint in patients with uncontrolled hypertension and moderate or severe (stage 3b/4) chronic [Read more]